slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 82,651-82,680
Pages 3,950
Rows per page 30
Component
82,651-82,680 of 118,471
294
The slide uses direct quotes from surgeons to validate the market share shift thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
295
The slide uses a direct quote from a surgeon to undermine the credibility and clinical utility of the TransMedics OCS device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
303
This is a text-only slide serving as a section header or key point in a research note.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
304
The slide uses direct quotes from surgeons to build a bearish case against the company (TransMedics/Waleed).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
305
The slide uses a 'laundry list' format to present competitive threats, supported by product imagery.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
306
The slide uses a 'villain' narrative structure to frame TransMedics as vulnerable to upcoming competition.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
307
The slide uses expert testimony to build a bearish case against the incumbent (TransMedics).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
308
The slide uses expert testimony to undermine the value proposition of TransMedics' portability.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
309
The slide uses direct quotes from an OrganOx employee and a leading transplant surgeon to validate the thesis.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
310
The slide uses direct quotes from transplant surgeons and hepatologists to validate the thesis of market disruption.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
311
The slide highlights a competitive threat to TransMedics driven by OPO purchasing behavior.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
313
The slide uses a direct quote to highlight a competitive threat to TransMedics' business model.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
314
The slide uses direct quotes from an organ procurement specialist to validate the thesis of market disruption.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
315
The slide uses direct quotes from a transplant surgeon to validate the thesis that TransMedics is at risk of being rendered obsolete by competitors.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
316
Includes verbatim transcripts from a transplant surgeon regarding competitive dynamics in the liver transplant market.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
318
The slide uses a combination of cost comparison and technical diagrams to argue for the obsolescence of the subject company's core product.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
319
The slide uses expert testimony to frame TransMedics as an overpriced incumbent being disrupted by a cheaper, established European technique (NRP).TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
320
The slide uses direct quotes from a consultation call to highlight the competitive threat of NRP to TransMedics.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
321
Includes citations from JAMA and American Journal of Transplantation.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
322
The slide contrasts the perceived limitations of TransMedics' technology with the functional advantages of NRP, supported by expert testimony and market evidence.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
323
The slide uses a 'canary in the coal mine' metaphor to frame the loss of a major customer as a leading indicator of broader market share erosion.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
324
The slide uses direct quotes from industry experts to validate the thesis of NRP market penetration.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
325
The slide uses a direct quote to frame the current market situation as overpriced and vulnerable to disruption, drawing an analogy to the Hepatitis C drug market.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
326
This slide functions as a 'villain critique' or 'fraud exposure' note, likely part of a short-seller research report.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
327
The slide uses direct quotes from former employees to build a case for corporate malfeasance and product failure.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
328
The slide uses a Q&A format to present testimony, highlighting specific instances of alleged misconduct.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
330
The slide uses direct quotes from former employees and industry peers to build a case against the reliability of the TransMedics OCS device.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
331
Includes a direct quote from a CEO of a major OPO regarding a surgeon's resignation due to safety concerns.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
333
The slide uses visual evidence (images of livers and CT scans) to support the argument that machine perfusion causes lasting tissue damage.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit
335
The slide uses a Q&A format to highlight a specific failure in the procurement process.TransMedics (TMDX) · Scorpion Capital
Research note Short seller 1 hit